Introduction {#s0005}
============

Indigent and minority women and those with multiple sexual partners are at particular risk for cervical cancer. These are also risk factors for infection with the human immunodeficiency virus (HIV), making HIV seropositivity a useful marker for cervical cancer risk. HIV increases HPV infections, abnormal Paps, and cervical cancer ([@bb0005]). Screening and precursor treatment reduce cancer risk even for women with HIV ([@bb0010]). However, cervical cancer prevention is complex, involving HPV vaccination, screenings, triage with HPV tests and colposcopy, and therapy. High risk women including those with HIV are often noncompliant ([@bb0015]). Understanding what women with HIV know about cervical cancer prevention may offer insights into how educational efforts might target high risk women.

Previous research involving a national cohort of women with HIV and comparison HIV-uninfected women demonstrated knowledge gaps related to risk factors for and consequences of HPV infection. These women also have limited understanding of cervical cancer prevention methods ([@bb0020], [@bb0025]). Knowledge correlated with HIV seropositivity, white ethnicity, higher income, more education, better reading skills, and prior abnormal Pap ([@bb0020]). Knowledge had little impact on colposcopy compliance ([@bb0030]), perhaps because knowledge remained suboptimal despite improving after an educational intervention ([@bb0025]).

Since vaccine introduction in 2006, marketing and media coverage have exposed many U.S. women to information about cervical cancer, HPV, and HPV vaccination ([@bb0035], [@bb0040]), but the impact of these messages on high risk women is unclear. This analysis extends prior research by exploring trends over time in knowledge and attitudes. In addition, we assessed knowledge in a cohort of women without prior experience with our questionnaire enrolled after HPV vaccine release.

Methods {#s0010}
=======

This investigation was a part of the Women\'s Interagency HIV Study (WIHS), an ongoing U.S. multicenter prospective cohort investigation of HIV infection among HIV seropositive women and seronegative comparison women at risk for HIV. Protocols, recruitment processes, procedures, and baseline results have been described ([@bb0045], [@bb0050]). Enrollment began with 2623 women in 1994--5 at 6 study consortia (Bronx, Brooklyn, Chicago, Los Angeles, San Francisco, and Washington, D.C.). To remain reflective of the demographics of the U.S. HIV epidemic, the cohort was expanded by 1143 additional women during 2001--2002 ([@bb0050]) and by 371 more in 2011--2012. This analysis compares information from three cross-sectional questionnaires administered in English April--October, 2007 (baseline), October, 2008--April, 2009 (follow-up), and April--October, 2011 (third administration). Results of the first two iterations have been described ([@bb0010], [@bb0025]). Following baseline administration, women were provided with correct answers and explanations as an educational intervention to assess its impact on knowledge.

The 44-item questionnaire included items related to knowledge of HPV, cervical cancer risks, HPV vaccine, and abnormal Pap tests. A change score analysis, using the paired *t*-test, was conducted to assess whether and to what extent individual knowledge scores improved between baseline and follow-up. Analysis of covariance models examined change in knowledge between baseline and follow-up. Independent variables included baseline score, HIV status, and demographic and medical characteristics including age at questionnaire administration, ethnicity, education by study entry, and household income. Each variable was evaluated for fit using the type III SS value and p-value and was included in analyses if p-value \< 0.05. Final models used the PROC Generalized Linear Models (GLM) procedure in SAS software 9.2 (SAS Institute Inc., Cary, NC). A separate analysis was conducted on only the third survey administration to evaluate for knowledge differences among recruitment waves. Chi-square tests compared recruitment cohorts by knowledge questions and final models were fit using similar techniques for the longitudinal analysis including recruitment wave as an independent variable.

Results {#s0015}
=======

Of 1451 women completing questionnaires in 2007, 974 (67%) completed three serial questionnaires. Of these, 652 (67%) were completed by HIV seropositive and 322 (33%) by seronegative women. Risk factors for cervical cancer including minority ethnicity, low annual income, and current or former smoking history were present in the majority of participants ([Table 1](#t0005){ref-type="table"}). When compared to HIV seronegative women, HIV seropositive women were older, more likely to be non-Hispanic white, and less likely to currently use alcohol, tobacco, or drugs.

Individual component results of questionnaires across the three recruitment waves are presented in [Table 1 Supplemental digital content](#ec0005){ref-type="supplementary-material"}, [Table 2 Supplemental digital content](#ec0010){ref-type="supplementary-material"}, [Supplemental Table 3](#ec0015){ref-type="supplementary-material"}. Mean knowledge scores increased across administrations, from 12.8 (S.D. 5.8) at baseline to 13.9 (5.3) at follow-up (P \< 0.0001) to 14.3 (S.D. 5.2) at third administration (P \< 0.0001 vs baseline and \< 0.04 vs follow-up). As scores are out of a possible 24, even improved later scores reflect limited knowledge. Lower baseline scores of HIV seronegative women (11.7 with S.D. 6.0) versus HIV seropositive women (13.3 S.D. 5.7, P \< 0.0001) were eliminated by the third questionnaire administration (13.9 with S.D. 5.3 among HIV uninfected vs 14.4 with S.D. 5.1 among HIV infected women, P = 0.12). No improvement in knowledge of HPV vaccine, its indications, or its target population was observed between the follow-up and third questionnaire administrations. Although small increases in knowledge were seen, at the third questionnaire administration only 56% of all women studied knew that Pap testing checked the cervix, 46% knew it should be repeated at 1--3 year intervals for women with HIV. In contrast, 83% of all women studied knew that annual Pap testing was indicated for women with HIV and prior negative screening, 79% knew that Pap testing checks for precancer and cancer, 74% knew that HPV is a sexually transmitted virus that causes genital warts and cancers, and 78% knew that women with HPV are at higher risk for cancer. These results were minimally changed from the follow-up administration of the questionnaire.

Independent factors associated with an improvement in knowledge score at the third, previously unreported administration of the survey included higher knowledge scores at first and follow-up administration of questionnaires, higher income, and higher education level ([Table 2](#t0010){ref-type="table"}). There was also a significant difference in knowledge score by site. R-squared for this model was 0.35, indicating that these factors explained approximately one third of the magnitude of change. HIV status was not significant after controlling for these factors, nor was drug use.

A cross-sectional analysis of the third administration of the survey evaluated knowledge among women in a recently enrolled cohort. The survey was completed by 1968 women (979 cohort 1, 734 cohort 2, 255 cohort 3). Overall there was a higher percentage of HIV seropositive women in the third compared to the first and second cohorts (82.5% vs 74.6% and 63.5%, P \< 0.0001). The average age in the first, second and third cohorts respectively were 51.4, 41.1, and 44.1 years. In addition, compared to the first and second cohorts, the third cohort was more likely to be non-Hispanic African-American, to have lower income, to report alcohol or drug use, and to be a current smoker. There also were differences in CD4 counts below 200 cells/mm^3^: cohort 1, 63.4%, cohort 2, 22.3%, cohort 3, 30.5, P \< 0.0001. Although mean scores did not differ between first and second enrollment cohorts (14.0 (S.D. 5.2) vs 13.8 (5.4), P = 0.27), scores were lower for the third (12.5 (5.8), P = 0.0001 vs the first cohort and P = 0.002 vs the second cohort). Specific differences among cohorts are presented in [Table 1 Supplemental digital content](#ec0005){ref-type="supplementary-material"}, [Table 2 Supplemental digital content](#ec0010){ref-type="supplementary-material"}, [Supplemental Table 3](#ec0015){ref-type="supplementary-material"}, but differences were present across all components of the questionnaire. Only 50--60% of women in all cohorts believed cervical cancer is preventable. Only about 60% of women in the first and second cohorts said that they had heard of the HPV vaccine ([Table 3, Supplemental digital content](#ec0015){ref-type="supplementary-material"}), although all had been informed during previous iterations of the questionnaire; only 43% of women in the third cohort said that they had heard of the HPV vaccine (P \< 0.0001). Despite this, some three fourths of all cohorts knew that the HPV vaccine was targeted to adolescents and teens. Furthermore, 71% of both the first and second enrollment cohorts knew that the vaccine prevented abnormal Pap tests and cervical precancer and cancer, though only 62% of women in the third cohort knew this (P = 0.01). A multivariable model demonstrated that being in the first or second recruitment cohort wave was associated with a higher knowledge score compared to those recruited in the last wave. In addition, being HIV positive or a former or current drug user, younger age, having a higher income or education level, and being a white non-Hispanic respondent was associated with higher knowledge scores ([Table 2](#t0010){ref-type="table"}).

Discussion {#s0020}
==========

Cervical cancer disproportionately afflicts poor and minority U.S. women, largely because they fail to receive screening. HPV vaccination lowers risk, but the U.S. vaccination program requires parents to elect vaccination for their children, which in turn requires understanding of risks and indications.

Among women at high cervical cancer risk, knowledge of cervical cancer prevention has improved, but gaps remain. Women newly enrolled into our cohort had knowledge scores lower than those of previously enrolled women but similar to baseline scores in prior cohorts, as previous administrations of the questions and an educational intervention involving provision of their answers improved knowledge ([@bb0025]). Nevertheless, appreciation of cervical cancer prevention processes among similar women outside the study is likely to be less than optimal to support informed screening compliance and election of HPV vaccination for themselves and their children.

Our results are similar to others\', though our study includes longitudinal results. Kelly and colleagues showed that despite a sharp increase in knowledge of the link between HPV and cervical cancer after vaccine introduction, knowledge leveled off below 60% ([@bb0035]). Joseph and associates found that only half of low-income women surveyed in 2007--2012 knew that HPV causes cervical cancer and that knowledge deficits were greater among minority women ([@bb0055]). Strohl et al. found low knowledge scores among Chicago African American women ([@bb0060]).

U.S. HPV vaccination rates are suboptimal, and African-American adolescents and young uninsured women are less likely to be vaccinated ([@bb0065]). Inadequate appreciation of vaccine benefits and risks pose a barrier to vaccination ([@bb0070]). Messages targeted to poor and minority women are needed to improve vaccination rates, and our results suggest that these messages may have to clarify very basic concepts.

Inclusion of women with HIV was a strength of the study. Such women are at particular risk, in part because of immunosuppression but also because they have multiple cancer risk factors such as smoking and multiple sexual partners. Other strengths include serial survey administration and the multisite cohort.

This study was limited by several factors. Women were participating in semiannual Pap screening as part of the WIHS, so we could not assess impact of knowledge on screening or vaccination. Screening guidelines changed after the 2011 administration of our questionnaire, and current understanding about screening intervals and tests might not reflect these new recommendations. Most study women were older than the target age for HPV vaccination, and we did not assess the impact of knowledge or attitudes on vaccination rates among young relatives who might be vaccination candidates. We could not determine whether differences between prior and most recent enrollees were due to longer experience with cervical cancer prevention in WIHS, familiarity with questionnaires, or other factors distinguishing enrollment cohorts. However, our finding that knowledge of cervical cancer prevention was lower among newest recruits indicates that passive learning from media, family and friends, and health care providers in recent years is insufficient. Finally, women enrolled in WIHS may be selected. However, women outside frequent care and women who have not dedicated themselves to a decade-long study are likely to be even less informed about cervical cancer prevention than participants in our study.

Not all items assessed in our question set may directly influence prevention and treatment behaviors. For instance, while women should be aware of guidelines on Pap frequency, knowing diet does not impact cervical cancer risk may be less important. Further research to better define determinants of HPV prevention and cervical cancer detection/treatment behaviors and to identify subgroups at greater risk based on these determinants may aid in designing and disseminating more effective strategies to improve these outcomes.

Misperceptions about cervical cancer prevention remain common among the largely poor and minority women in our study. While specific educational efforts may improve understanding and prevention behavior, school based or mandatory HPV vaccination may have greater long-term impact. Opt-out approaches may yield better vaccination rates than opt-in approaches that require weighing of vaccine benefits and risks. Long-term progress against cervical cancer may require additional messages on providing women at high risk for cervical cancer with the understanding they need to enroll their children in routine HPV vaccination programs.
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###### 

Baseline demographic and medical characteristics of women who completed questionnaires at three consecutive surveys (n = 974). n (%).

  ----------------------------------------------------------------------------------------------------------------------------------
                                                                HIV +\       HIV −\       P-value[a](#tf0005){ref-type="table-fn"}
                                                                N = 652      N = 322      
  ------------------------------------------------------------- ------------ ------------ ------------------------------------------
  Age at baseline interview (years)                                                       

   \< 30                                                        5 (0.8)      30 (9.3)     \< 0.0001

   30--39                                                       116 (17.8)   85 (26.4)    

   40--49                                                       268 (41.1)   110 (34.2)   

   50 +                                                         263 (40.3)   97 (30.1)    

  Ethnicity                                                                               

   Non-Hispanic African American                                418 (64.1)   205 (63.6)   0.0054

   Hispanic                                                     115 (17.7)   78 (24.2)    

   Non-Hispanic White                                           94 (14.4)    25 (7.8)     

   Other                                                        25 (3.8)     14 (4.4)     

  Average annual household income (n = 941)                                               

   \<=\$6000                                                    78 (12.3)    59 (19.3)    0.0011

   \$6001--\$12,000                                             224 (35.3)   77 (25.2)    

   \$12,001--\$18,000                                           69 (10.8)    45 (14.7)    

   \$18,001 +                                                   264 (41.6)   125 (40.8)   

  Education level (n = 973)                                                               

   Less than high school                                        213 (32.7)   109 (34.0)   0.3743

   Completed high school                                        201 (30.8)   109 (34.0)   

   Some college/college degree                                  238 (36.5)   103 (32.0)   

  Site/location                                                                           

   Bronx                                                        101 (15.5)   60 (18.6)    0.0017

   Brooklyn                                                     201 (30.8)   69 (21.4)    

   Washington DC                                                97 (14.9)    44 (13.7)    

   Los Angeles                                                  72 (11.0)    58 (18.0)    

   San Francisco                                                87 (13.4)    54 (16.8)    

   Chicago                                                      94 (14.4)    37 (11.5)    

  Alcohol use                                                                             

   Abstainer                                                    371 (56.9)   133 (41.3)   \< 0.0001

   Light (\< 3 drinks/week)                                     200 (30.7)   111 (34.5)   

   Moderate/heavy (3 + drinks/week)                             81 (12.4)    78 (24.2)    

  Current smoker                                                                          

   Current user                                                 235 (36.0)   143 (44.4)   0.0197

   Former user                                                  226 (34.7)   107 (33.2)   

   Never                                                        191 (29.3)   72 (22.4)    

  Injection drug use status                                                               

   Current user                                                 4 (0.6)      8 (2.5)      0.0361

   Former user                                                  42 (6.5)     24 (7.5)     

   Never                                                        606 (92.9)   290 (90.0)   

  Non-injection drug use status                                                           

   Current user                                                 119 (18.3)   94 (29.2)    \< 0.0001

   Former user                                                  242 (37.1)   132 (41.0)   

   Never                                                        291 (44.6)   96 (29.8)    

  Lifetime nadir CD4 lymphocyte count (cells/mm^3^) (n = 626)                             

   \< 200                                                       200 (32.0)                

   200--500                                                     349 (55.7)                

   \> 500                                                       77 (12.3)                 

  CD4 lymphocyte count (cells/mm^3^) at visit (n = 642)                                   

   \< 200                                                       75 (11.7)                 

   200--500                                                     197 (30.7)                

   \> 500                                                       370 (57.6)                
  ----------------------------------------------------------------------------------------------------------------------------------

By chi-square test.

###### 

Analysis of Covariance Models assessing factors associated with cervical cancer prevention knowledge score at third survey administration among high risk women. Both models controlled for study site.

                                        Model for women completing all 3 survey administrations N = 974   Model for women who completed the third survey administration N = 1968
  ------------------------------------- ----------------------------------------------------------------- ------------------------------------------------------------------------
  Adjusted R^2^                         0.35                                                              0.10
  F-value                               46.98[⁎⁎⁎](#tf0020){ref-type="table-fn"}                          18.2[⁎⁎⁎](#tf0020){ref-type="table-fn"}
                                                                                                          
  Predictor variables                                                                                     
  Intercept                             8.94 (7.47, 10.40)[⁎⁎⁎](#tf0020){ref-type="table-fn"}             15.69 (14.60, 16.79)
  Total baseline score (1st)            0.27 (0.22, 0.33)[⁎⁎⁎](#tf0020){ref-type="table-fn"}              
  Total follow-up score (2nd)           0.28 (0.22, 0.34)[⁎⁎⁎](#tf0020){ref-type="table-fn"}              
  Recruitment cohort (vs 3rd cohort)                                                                      
  Cohort 1                                                                                                1.12 (0.36, 1.88)[⁎⁎](#tf0015){ref-type="table-fn"}
  Cohort 2                                                                                                0.96 (0.20, 1.71)[⁎](#tf0010){ref-type="table-fn"}
  HIV seropositive (vs negative)        − 0.18 (− 0.75, 0.39)                                             0.52 (− 0.003, 1.03)
  Age less than 50 (vs 50 + years)                                                                        0.71 (0.17, 1.24)[⁎⁎](#tf0015){ref-type="table-fn"}
  Ethnicity (vs White NH)                                                                                 
   Non-Hispanic African American                                                                          − 1.76 (− 2.52, − 1.00)[⁎⁎⁎](#tf0020){ref-type="table-fn"}
   Hispanic                                                                                               − 1.50 (− 2.36, − 0.64)[⁎⁎⁎](#tf0020){ref-type="table-fn"}
   Other                                                                                                  − 1.61 (− 2.95, − 0.27)[⁎⁎](#tf0015){ref-type="table-fn"}
  Education (vs College)                                                                                  
   Less than high school                − 0.88 (− 1.57, − 0.18)[⁎](#tf0010){ref-type="table-fn"}          − 2.61 (− 3.20, − 2.03)[⁎⁎⁎](#tf0020){ref-type="table-fn"}
   Completed high school                − 0.10 (− 0.76, 0.57)                                             − 0.96 (− 1.55, − 0.37)[⁎⁎⁎](#tf0020){ref-type="table-fn"}
  Income \< \$18,000 (vs \> \$18,000)   − 0.82 (− 1.41, − 0.24)[⁎⁎](#tf0015){ref-type="table-fn"}         − 1.27 (− 1.79, − 0.75)[⁎⁎⁎](#tf0020){ref-type="table-fn"}
  Drug use (vs never)                                                                                     
   Former user                                                                                            0.85 (0.30, 1.39)[⁎⁎](#tf0015){ref-type="table-fn"}
   Current user                                                                                           0.61 (− 0.01, 1.22)

p \<= 0.05.

p \<= 0.01.

p \<= 0.001.
